ACTG A5095 -PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是了解每种药物组合降低血液中艾滋病毒数量并保持在较低水平的效果如何，以及这些药物组合的耐受性有多好，以及它们是否安全。受试者必须从未服用过抗艾滋病毒药物，并且病毒载量超过400份。随机分为以下治疗组：A组：ABC+3TC+ZDV联合片3TC+ZDV安慰剂(非活性药物)EFV胶囊；B组：ABC+3TC+ZDV联合片3TC+ZDV安慰剂EFV胶囊；C组：ABC+3TC+ZDV安慰剂3TC+ZDV联合片EFV胶囊。这项研究持续了大约3.5年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn how well each combination of drugs lowers the amount of HIV in the blood and keeps it low and how well the drug combinations are tolerated and if they are safe. Subjects must be never have taken anti-HIV drugs, and have a viral load greater than 400 copies. Subjects will be randomized by chance to one of the following treatment groups: Group A: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet (no active drug) EFV capsules once daily; Group B: ABC+3TC+ZDV combination tablet 3TC+ZDV placebo tablet EFV placebo capsules; Group C: ABC+3TC+ZDV placebo 3TC+ZDV combination tablet EFV capsules. This study lasts about 3.5 years.